Fenofibrate inhibit the development of malaria in Plasmodium berghei-infected mice
Malaria, an infectious disease begins with the introduction of protists into blood circulation and may cause death in severe cases. Development of resistance in Plasmodium parasites is major obstacle and emphasizes the need of novel strategy to combat the prevalent of disease. Fenofibrate, an agonist of peroxisome proliferator-activated receptor alpha (PPAR-α) is well known to treat hypertriglyceridaemia and mixed dyslipidaemia from decades. Recent studies reports possibility of its activity against the malarial parasite as well. Here we explore the Fenofibrate for activity against malaria in Plasmodium berghei infected mice The infected erythrocytes (IE) from control and treated mice was subjected to microscopic examination for analyse the mean percent parasitemia on day 4th, 7th, 10th, 14th and 21st after infection. The results of present study illustrate the activity of fenofibrate against Plasmodium berghei malaria parasite in-vivo. Significant distinction was observed in percent parasitemia of fenofibrate and vehicle treated mice. Treatment with 320mg/kg was found to be most suppressing amongst the entire treatments of fenofibrate.
Full Text Attachment